Sucampo Pharmaceuticals, Inc. Announces Second Quarter 2014 Financial Results and Corporate Update Teleconference and Webcast...
July 22 2014 - 6:45AM
Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global
biopharmaceutical company, today announced that it will host its
second quarter 2014 financial results teleconference and webcast at
8:30 a.m. Eastern on Tuesday, August 5, 2014. As part of the
corporate update, CEO Peter Greenleaf will discuss the results of
his strategic review, including his vision for the company going
forward. Sucampo will distribute a news release announcing the
second quarter 2014 financial results and operating highlights
before the U.S. capital markets open on August 5, 2014.
Individuals interested in accessing the live audio webcast of
the teleconference may do so at
http://investor.sucampo.com/phoenix.zhtml?c=201197&p=irol-calendar
and should log on 10 to 15 minutes before the teleconference begins
to download any software required. Presentation slides will be
available via the webcast link. A replay of the webcast will also
be available on Sucampo's website for several days after the live
event. Alternatively, individuals may dial 877-703-6104 (domestic)
or 857-244-7303 (international) and use passcode 29794935. A replay
of the teleconference will be available by dialing 888-286-8010
(domestic) or 617-801-6888 (international), passcode 95005218,
approximately two hours after the teleconference concludes. The
archive of the teleconference will be available for 30 days.
About Sucampo Pharmaceuticals, Inc.
Sucampo Pharmaceuticals, Inc. is focused on the discovery,
development and commercialization of medicines to meet the major
unmet medical needs of patients on a global basis. Sucampo has two
marketed products – AMITIZA® and RESCULA® – and a pipeline of
product candidates in clinical development. A global company,
Sucampo is headquartered in Bethesda, Maryland, and has operations
in Japan, Switzerland and the United Kingdom. For more information,
please visit www.sucampo.com.
The Sucampo logo is the registered trademark and the tagline,
The Science of Innovation, is a pending trademark of Sucampo AG.
AMITIZA is a registered trademark of Sucampo AG. RESCULA is a
registered trademark of R-Tech Ueno, Ltd, and has been licensed to
Sucampo AG.
Follow us on Twitter (@Sucampo_Pharma). Follow us on LinkedIn
(Sucampo Pharmaceuticals).
Twitter
LinkedIn
Sucampo Forward-Looking Statement
This press release contains "forward-looking statements" as that
term is defined in the Private Securities Litigation Reform Act of
1995. These statements are based on management's current
expectations and involve risks and uncertainties, which may cause
results to differ materially from those set forth in the
statements. The forward-looking statements may include statements
regarding product development, product potential, future financial
and operating results, and other statements that are not historical
facts. The following factors, among others, could cause actual
results to differ from those set forth in the forward-looking
statements: the impact of pharmaceutical industry regulation and
health care legislation; the ability of Sucampo to develop and
commercialize existing and pipeline products; Sucampo's ability to
accurately predict future market conditions; dependence on the
effectiveness of Sucampo's patents and other protections for
innovative products; the risk of new and changing regulation and
health policies in the U.S. and internationally and the exposure to
litigation and/or regulatory actions.
No forward-looking statement can be guaranteed and actual
results may differ materially from those projected. Sucampo
undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events,
or otherwise. Forward-looking statements in this presentation
should be evaluated together with the many uncertainties that
affect Sucampo's business, particularly those mentioned in the risk
factors and cautionary statements in Sucampo's most recent Form
10-K as filed with the Securities and Exchange Commission on March
12, 2014 as well as its filings with the Securities and Exchange
Commission on Form 10-Q and 8-K, which Sucampo incorporates by
reference.
CONTACT: Silvia Taylor
Senior Vice President, Investor Relations and
Corporate Communications
Sucampo Pharmaceuticals, Inc.
1-240-223-3718
staylor@sucampo.com
Sucampo Pharmaceuticals, Inc. (delisted) (NASDAQ:SCMP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sucampo Pharmaceuticals, Inc. (delisted) (NASDAQ:SCMP)
Historical Stock Chart
From Apr 2023 to Apr 2024